Clinicopathological Features and Clinical Outcomes of Metastatic Adenocarcinoma of Unknown Primary: A Single Center Experience
Received Date : 17 May 2022
Accepted Date : 18 Oct 2022
Available Online : 07 Nov 2022
Doi: 10.37047/jos.2022-91381 - Article's Language: EN
J Oncol Sci. 2022;8(3):119-26
This is an open access article under the CC BY-NC-ND license
Objective: This study aimed to investigate the clinical outcomes of site-specific therapy (SST) in patients with metastatic adenocarcinoma of unknown primary (MACUP). Material and Methods: A retrospective observational study was conducted, including patients diagnosed with MACUP. Clinicopathological features and clinical outcomes of SST were evaluated. Results: Sixty patients were included in the study. The median age was 61.5 (minimum-maximum: 31.1-76.1) years, and 40.0% of the patients (n=24) were 65 years or older. The progression- free survival (mPFS) was 4.7 months [95% confidence interval (CI): 3.7-5.7] with the first-line treatment in the whole group. The mPFS was 4.1 months (95% CI: 2.9-5.2), 4.7 months (95% CI: 3.0-6.3), and 9.3 months (95% CI: 6.1-12.6) in the gemcitabine plus cisplatin, carboplatin plus paclitaxel, and mFOLFOX-6 groups, respectively. The overall survival (mOS) was 14.1 months (95% CI: 9.2-18.8) in the whole group. The mOS was 9.2 months (95% CI: 3.3-14.3), 8.5 months (95% CI: 3.8-13.2), and 15.5 months (95% CI: 9.3-18.8) in the gemcitabine plus cisplatin, carboplatin plus paclitaxel, and mFOLFOX-6 groups, respectively. Conclusion: Patients with colorectal-derived cancers of our cohort, considered as a “more sensitive” type, seemed to benefit more from immunohistochemistry-based (IHC-based) SST. However, SST determination using genomic profiling is a gold standard, and IHC also offered valuable information.
  1. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G; ESMO Guidelines Committee. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. Sep 2015;26 Suppl 5:v133-138. [Crossref]  [PubMed] 
  2. Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. Aug 2019;61:139-141. [Crossref]  [PubMed] 
  3. Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 2020;17(9):541-554. [Crossref]  [PubMed] 
  4. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428-1435. [Crossref]  [PubMed] 
  5. Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012;23(7):1854-1863. [Crossref]  [PubMed] 
  6. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol. 2007;46(5):592-601. [Crossref]  [PubMed] 
  7. Moran S, Martínez-Cardús A, Sayols S, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(10):1386-1395. [PubMed] 
  8. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31(2):217-223. [Crossref]  [PubMed] 
  9. Hayashi H, Kurata T, Takiguchi Y, et al. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol. 2019;37(7):570-579. [Crossref]  [PubMed] 
  10. Fizazi K, Maillard A, Penel N, et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Annals of Oncology. 2019;30(Supplement 5):v851. [Crossref] 
  11. Ding Y, Jiang J, Xu J, et al. Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open. 2022;7(2):100407. [Crossref]  [PubMed]  [PMC] 
  12. Rassy E, Bakouny Z, Choueiri TK, et al. The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. Eur J Cancer. Mar 2020;127:118-122. [Crossref]  [PubMed] 
  13. Li X, Shao Y, Sheng L, et al. Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site. Cancer Med. 2021;10(3):974-988. [Crossref]  [PubMed]  [PMC] 
  14. Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer. 2012;11(2):112-118. [Crossref]  [PubMed]